The NanoLYRIC project: nanoparticles as drug carriers - 13/08/2026

Radiation-activated local chemotherapy

Conventional chemotherapy is associated with severe side effects because cytotoxic drugs act on the whole body. Researchers at the Karlsruhe Institute of Technology and the University Medical Centre Göttingen, in collaboration with Aalen University of Applied Sciences, are developing a novel approach in which a chemotherapeutic agent encapsulated in nanoparticles is released locally and selectively only upon targeted irradiation of the tumour.

A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.

Over the next five years, Dr. Mykhailo Batiuk and his research group at the Heidelberg Faculty of Medicine at Heidelberg University will investigate the biological mechanisms underlying post-traumatic stress disorder. The European Research Council (ERC) is supporting the project with an ERC Starting Grant worth approximately €1.4 million.

Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.

EMUNO Therapeutics: the innate immune system as a new approach to cancer treatment - 29/07/2026

Activation of macrophages: a key factor in the fight against colorectal cancer

The mobilisation of the body’s own immune system through immune checkpoint inhibitors has revolutionised cancer therapy. However, the majority of solid tumours are able to evade immune surveillance. These so-called 'cold' tumours contain too few immune cells to respond effectively to current immunotherapies. This is where the Freiburg-based biotech start-up EMUNO Therapeutics GmbH comes in.

On July 24, 2026, the Medical Center – University of Freiburg, the University of Freiburg, and the medical technology company Siemens Healthineers opened their joint Technology Innovation Lab, for short. In the lab at the Department of Radiation Oncology, experts in medicine, medical physics, radiation biology, and data science are working together with engineers to develop and test new technologies for radiation therapy to treat cancer.

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development.

It has long been suspected that endothelial cells play a key role in determining how the body’s immune system responds to tumors. Researchers at the DKFZ and the Medical Faculty Mannheim of Heidelberg University have now identified, in mouse studies, a specialized population of blood vessel lining endothelial cells that enable an effective immune defense against cancer metastases in the liver.

Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies.

CRISPR base editing for tailored tumour treatment - 16/07/2026

Targeted genetic manipulation of signal transduction pathways in CAR T cells enhances anti-tumour potency

Chimeric antigen receptor (CAR) T cell therapy has emerged as a highly promising treatment modality but has so far been used almost exclusively for advanced haematologic malignancies. Researchers at the iFIT cluster of excellence in Tübingen have now used CRISPR base-editing technology to introduce precise point mutations into key signalling pathways of CAR T cells, significantly enhancing their long-term persistence and anti-tumour potency.

Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines.

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.

Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.

A team led by researchers from the German Cancer Research Center and the HI-STEM* Stem Cell Institute has discovered a new approach to treating advanced colorectal cancer. The study identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells.

On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.

On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.

Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

The European Research Council (ERC) supports visionary projects in basic research through its “Advanced Grants.” This year, the Council awarded a grant to cancer researcher and physician Dieter Saur from the DKTK Munich* site, and Aurelio Teleman, a metabolism expert at the German Cancer Research Center (DKFZ).

Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the ERC, which will support a project in the field of computational quantum chemistry. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola.

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.